Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering’s mission of ending cancer for life is a bold one, but vital to anyone experiencing a cancer diagnosis. We depend on collaboration from health insurers to continue this mission, but Anthem BCBS has been ignoring what it takes to deliver MSK’s exceptional care. MSK board member John Strangfeld shares how MSK is working hard to come to an agreement with Anthem. Read more: https://njersy.co/4i0vFNT

Twenty-nine researchers from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute (SKI) are on Clarivate's Highly Cited Researchers 2024 list, demonstrating significant influence in their chosen field by publishing multiple Highly Cited Papers™ in their areas of expertise in the past decade. Their papers are ranked in the top 1% by citations for their field and year. Some of the researchers include Dr. Mark Awad, Dr. Luis Diaz, Dr. Alexander Drilon, Dr. Jonathan Rosenberg, and Dr. Eileen O’Reilly. View the full list below, and please join us in celebrating our colleagues in the comments 👏 https://bit.ly/3CMDiax

The FDA has approved revumenib for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called a KMT2A translocation. Dr. Eytan Stein, an expert in early drug development and Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), led the trial that brought about the drug's approval. Revumenib is the first drug in a new class called menin inhibitors to receive FDA approval. Learn more: https://bit.ly/3V0eBxV

Dr. Joan Massagué, Director of the Sloan Kettering Institute (SKI) and Chief Scientific Officer for Memorial Sloan Kettering Cancer Center (MSK), is known for his research in cancer biology. A lesser known place where Dr. Massagué is in his element outside of a research lab: among fellow rockhounds enchanted by the beauty of crystals. At its most expansive, Dr. Massagué’s collection numbered over 1,000 specimens. Today, it’s down to a trim 400 — most of them measuring just a few inches. These he keeps on display at his home in glass-fronted cabinets. Both his work as a biologist and as a rock hunter involve painstaking detective work. “It requires patience,” Dr. Massagué says. “There’s no right or wrong. There is no one style. Just like with the SKI, I’m interested in letting the component parts help each other — so that the whole becomes more than the sum of the parts.” Read more about Dr. Massagué: https://bit.ly/4eHHdmz

Looking to make the next groundbreaking discovery in cancer and biomedical sciences? The Gerstner Sloan Kettering Graduate School of Biomedical Sciences at Memorial Sloan Kettering Cancer Center is accepting applications for their Cancer Biology and Cancer Engineering programs. The deadline to apply is Sunday, 12/1. Apply now: https://bit.ly/4fnQ4uJ

Join thoracic oncology experts from Memorial Sloan Kettering Cancer Center (MSK) this weekend at the NY Lung Cancers Symposium, including Dr. Helena Yu, Dr. Alexander Drilon, Dr. Gregory Riely, and more as they speak about the latest in lung cancer treatment and research. Learn more here: https://bit.ly/4ewpNZNCon

What's your risk of getting lung cancer if you're a woman who has never smoked? Dr. Helena Yu, a thoracic oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center (MSK), shares why #lungcancer is more common in women than men in the 35-to-54 age group and why people can get lung cancer even if they’ve never smoked. https://bit.ly/4ew1VWu

Interested in completing a PGY2 Pharmacy Residency at Memorial Sloan Kettering Cancer Center (MSK)? MSK will host virtual information sessions for PGY2 Pharmacy Residency Programs on Tuesday, 11/19. Learn more about MSK's pharmacy programs and have the opportunity to meet program directors. Register here: https://lnkd.in/e7YEc9yi

In a new paper published in Nature Magazine, researchers at Memorial Sloan Kettering Cancer Center (MSK) are demonstrating that cancer outcome predictions can be improved by breaking down hospitals’ traditional data silos with the help of artificial intelligence (#AI). Learn more: https://lnkd.in/gCXK828y

“We were improvising on the fly. His whole treatment was very much like jazz music.” Learn how expert pathologists at Memorial Sloan Kettering Cancer Center used genomic testing to cure a renowned musician's cancer and how his remarkable case has led to a new way to treat patients: https://bit.ly/3CluMPG